ClinicalTrials.gg
Enrolling by invitationNCT07713901Updated Aug 4, 2026

Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma

An observational study in Medullary Thyroid Carcinoma, sponsored by Novo Nordisk A/S. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by Novo Nordisk A/S · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
93,600,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 81 studies in Carcinoma, Medullary with a site in United States — 12 open to participants now, 24 under way, 1 of them phase 3. Carcinoma, Medullary · United States.

Planned enrollment
Largest of 10
93,600,000 · median 413
Started
2025
with 4 others
Observational
10 of 81
5 open now
Primary completion
2026-12
later than 8 of 22 live
Registered
80th of 81
by date
Lead sponsor
2 of 81
Novo Nordisk A/S

Among the 81 studies in Carcinoma, Medullary with a site in United States, this one has the largest planned enrollment of the 10 observational ones that give a count, is one of 5 that started in 2025, is one of 10 observational ones, reaches primary completion later than 8 of the 22 other live ones, and was the 80th registered.

Carcinoma, Medullary

144 studies on the registry are indexed under Carcinoma, Medullary; 30 are open to participants now.

Browse Carcinoma, Medullary studies →

Open to participants now

12 of the 81 studies in Carcinoma, Medullary with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Carcinoma, Medullary studies recruiting now, 9 (56%) set no upper age limit and 3 (19%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Carcinoma, Medullary with a site in United States, or all of them as a file.
02

Study summary

This is a database linkage study utilizing real-world data (RWD) to determine whether certain medicines used to treat type 2 diabetes (T2D) and support weight management (called GLP-1 RAs (Glucagon-like peptide-1 receptor agonists )) are linked to an increased risk of a rare cancer called medullary thyroid carcinoma (MTC). The purpose of this study is to compare how often medullary thyroid cancer occurs in people taking these medicines versus those taking other similar treatments. This study will use dispensed prescription claims and State Cancer Registry data to assess the risk of MTC.

03

Conditions studied

  • Medullary Thyroid Carcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of adults aged 18 years and older in the United States who are receiving routine treatment for type 2 diabetes or weight management and are identified utilizing real-world data (RWD).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older during the year of index (date of qualifying medication)
  • In addition to index medication, greater than or equal to (≥) 1 dispensed medication (any class) within 24 months prior to the index date1
  • ≥1 dispensed medication (any class) after the index date and within 12 months of index date (12-month post-index period)
  • No evidence of cohort qualifying medication during 12-month before the index date
  • Reside in the US, including the District of Columbia (DC) during the study period
  • No missing values for year of birth

Exclusion criteria

Exclusion Criteria:

  • Patients with a diagnosis of MTC in the linked SCR data before their index date will not be included in the study.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
93,600,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Long-acting GLP-1 RA Exposed Cohort

    Participants will be eligible for inclusion in this cohort if they have at least one dispensed prescription for a LA GLP-1 RA therapy during the study patient selection period.

    Other: No treatment given

  • T2D Active Comparator 1 Cohort

    Participants will be included in this cohort if they fill at least one dispensed prescription for SGLT2 or DPP-4 inhibitors during the study patient selection period with no evidence of SGLT2 or DPP-4 inhibitors and without LA GLP-1 RA use during the prior 12-month lookback period.

    Other: No treatment given

  • T2D Active Comparator 2 Cohort

    Participants will be included in this cohort if they fill at least one dispensed prescription for any antidiabetic medications (including SGLT2 or DPP-4 inhibitors), other than LA GLP-1 RA therapies during the study patient selection period with no evidence of the cohort qualifying medication during the prior 12-month lookback period.

    Other: No treatment given

  • Overweight/Obesity Active Comparator Cohort

    Participants will be included in this cohort if they fill at least one dispensed prescription for anti-obesity medications, other than LA GLP-1 RA therapies during the study patient selection period with no evidence of the cohort qualifying medication during the prior 12-month lookback period.

    Other: No treatment given

Interventions

  • OtherNo treatment given

    No treatment given

06

What researchers measure

Primary outcomes

  1. Time to first occurence of Medullary Thyroid Carcinoma (MTC)

    Measured in number of days.

    Time frame: From day 1 up to 15 years

07

Study locations

1 site
  • IQVIA
    Parsippany, New Jersey 07054, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2026
First posted
Jul 20, 2026
StartActual
Dec 31, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07713901
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jul 20, 2026
Start date
Dec 31, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 4, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion